Birch Polypore

Metadata

Regulatory Status

Current

• No formal regulatory status in any jurisdiction for medicinal use
• Available as dietary supplement in some markets
• Widely available in the wild across birch forests of Northern Hemisphere (not endangered)
• No conservation concern — common species on birch trees throughout temperate/boreal regions

Historical

• Used in European folk medicine for centuries
• Valued as a strop for sharpening razors (hence “Razor Strop Fungus”) — the smooth underside surface provided an ideal stropping surface
• Used as wound dressing, styptic, and fire-carrying material (amadou)

Historical Significance: Otzi the Iceman

The discovery of Otzi (also spelled Otzi) in 1991 in the Tyrolean Alps provided the oldest documented evidence of medicinal mushroom use:

1. Date: ~3300 BC (Copper Age / Chalcolithic)
2. Discovery: Two pieces of Fomitopsis betulina were found threaded on leather thongs among Otzi’s possessions
3. Hypotheses for use:
   • Vermifuge (antiparasitic): Otzi was found to harbor Trichuris trichiura (whipworm) eggs in his intestinal contents. Birch polypore contains compounds with demonstrated antiparasitic activity, and its laxative/purgative properties could help expel intestinal parasites. This is the most widely accepted hypothesis.
   • Wound dressing: The soft, absorbent flesh of the polypore could serve as a bandage material. Otzi had multiple wounds and a fatal arrowhead lodged in his shoulder.
   • Fire-starting (amadou): Birch polypore trama can serve as tinder. However, Otzi also carried true tinder fungus (Fomes fomentarius), making this less likely as the sole purpose.
4. Significance: This discovery predates the earliest written medicinal mushroom records by over 3,000 years, establishing fungi as among the oldest documented medicines in human history.

Reference: Peintner U, Poder R, Pumpel T. The Iceman’s fungi. Mycol Res. 1998;102(10):1153-1162; Capasso L. 5300 years ago, the Ice Man used natural laxatives and antibiotics. Lancet. 1998;352(9143):1864.

Conditions & Indications

Primary (Preclinical + Historical)

• Anti-inflammatory — Polyporenic acids A and C demonstrate potent COX-2 and NF-kB inhibition in vitro. Anti-inflammatory activity is the most consistently demonstrated bioactivity across modern studies. Relevant to the traditional use for wound inflammation and GI complaints.
• Antimicrobial — Piptamine (piperidinyl alkaloid unique to F. betulina) shows broad-spectrum antibacterial activity. Aqueous and ethanol extracts demonstrate activity against Bacillus subtilis, Escherichia coli, Staphylococcus aureus, and others. Relevant to traditional wound-dressing use.
• Antiparasitic (vermifuge) — The Otzi hypothesis is supported by in vitro antiparasitic activity and the mild laxative properties of agaric acid content that could aid parasite expulsion.

Secondary (Preclinical)

• Antitumor — Betulinic acid (derived from birch substrate) demonstrates selective cytotoxicity against melanoma and other cancer cell lines via mitochondrial apoptosis pathway. Polysaccharide-mediated immunostimulatory antitumor effects in sarcoma 180 models.
• Antiviral — Betulinic acid and derivatives show anti-HIV activity (maturation inhibitor); polyporenic acids show activity against influenza viruses in vitro.
• Wound healing — Traditional use supported by antimicrobial activity, anti-inflammatory triterpenoids, and physical properties (absorbent, conformable wound dressing material).

Emerging/Preclinical

• Immunomodulation — Beta-glucan polysaccharides activate Dectin-1/TLR2 pathways
• Adaptogenic/General tonic — European folk medicine tradition for general health maintenance; mechanistic basis unclear but the broad anti-inflammatory and immunomodulatory profile is consistent with adaptogenic activity

Mechanism of Action

Primary Mechanisms

1. Polyporenic acid anti-inflammatory activity: Polyporenic acids A and C (lanostane-type triterpenoids) inhibit NF-kB nuclear translocation, suppressing transcription of pro-inflammatory genes (COX-2, iNOS, TNF-alpha, IL-1beta, IL-6). Additionally inhibit 5-lipoxygenase (5-LOX), reducing leukotriene synthesis. The dual COX-2/5-LOX inhibition profile is pharmacologically significant as it addresses both prostaglandin and leukotriene inflammatory pathways.

2. Piptamine antibiotic activity: Piptamine is a piperidinyl alkaloid unique to F. betulina with broad-spectrum antibacterial activity. It disrupts bacterial membrane integrity, likely through electrostatic interaction with negatively charged bacterial membrane phospholipids. Piptamine is active against both Gram-positive and Gram-negative bacteria at MIC values in the low micromolar range.

3. Betulinic acid anticancer mechanism: Betulinic acid (a pentacyclic lupane-type triterpenoid derived from birch bark and concentrated by the fungus) selectively induces apoptosis in cancer cells through the mitochondrial (intrinsic) pathway — permeabilization of the outer mitochondrial membrane, cytochrome c release, caspase cascade activation. Shows selectivity for cancer cells over normal cells. Phase I/II clinical trials of betulinic acid derivatives (bevirimat) have been conducted for HIV, demonstrating that the compound class has clinical translation potential.

4. Polysaccharide immunostimulation: Beta-1,3/1,6-D-glucans activate Dectin-1/TLR2/CR3 innate immune pathways, enhancing macrophage and NK cell activity (shared mechanism across medicinal mushrooms).

Secondary Mechanisms

5. Ergosterol peroxide anti-inflammatory activity: Inhibits LPS-induced inflammatory responses in macrophages through suppression of NF-kB and MAPK signaling.
6. Mild laxative/purgative activity: Agaric acid content (lower than in agarikon) provides mild cathartic effect, potentially relevant to the Otzi vermifuge hypothesis.

Clinical Evidence Summary

CRITICAL: No Human Clinical Trials Exist

All modern evidence is preclinical (in vitro and in vivo animal studies).

Key Preclinical Studies

Evidence Limitations

• No human clinical trials — the most critical limitation
• All bioactivity data is from in vitro assays and animal models
• Betulinic acid content varies depending on birch substrate species and growing conditions
• Piptamine has not been studied in vivo in mammals
• The Otzi vermifuge hypothesis, while compelling, is archaeological interpretation, not clinical evidence
• European folk medicine traditions are largely undocumented in formal medical literature

Safety Profile

General Assessment

Long history of human use in European folk medicine and as a tool (strop, fire-starter, wound dressing) without documented serious adverse effects. However, no formal toxicology studies have been conducted.

Contraindications

• Known allergy to Fomitopsidaceae or Polyporales fungi
• Pregnancy and lactation (no data)

Drug Interactions

• No clinically documented interactions
• Theoretical: anti-inflammatory triterpenoids may interact with NSAIDs (additive); betulinic acid may interact with antiretrovirals (HIV maturation inhibitor mechanism); immunostimulatory polysaccharides may antagonize immunosuppressants
• Overall risk assessed as low

Side Effects

• GI effects: Mild laxative effect possible at higher doses (agaric acid content lower than in agarikon)
• Other: No documented adverse effects from traditional use

Toxicology

• No formal toxicology studies (LD50, mutagenicity, etc.)
• Long history of use as wound dressing (topical) and dietary supplement suggests low toxicity
• Betulinic acid has been assessed in Phase I clinical trials (for HIV) and showed acceptable safety

Clinical Dosage

Traditional Preparations

• Tea/Decoction: Sliced dried polypore simmered 1-2 hours; European folk practice
• Wound dressing: Fresh fruiting body sliced thin and applied directly to wounds (traditional use)
• Tincture: Dried polypore extracted in alcohol/water; no standardized preparation
• Direct consumption: Tough texture limits palatability; traditionally simmered or dried and powdered

Modern Supplement

• Dried powder: 1-3 g/day in capsules (based on general medicinal mushroom dosing; no clinical validation)
• Dual extract: Hot water + ethanol extraction recommended to capture both polysaccharides and triterpenoids
• No clinically validated dose exists

Quality Considerations

• Widely available in the wild (not endangered); wild-harvested specimens can be used sustainably
• Betulinic acid content depends on birch substrate — specimens from Betula pubescens vs. B. pendula may differ
• Fresh specimens have different bioactive profiles than dried/extracted products

Sources

Archaeological / Historical

• Peintner U, Poder R, Pumpel T. The Iceman’s fungi. Mycol Res. 1998;102(10):1153-1162
• Capasso L. 5300 years ago, the Ice Man used natural laxatives and antibiotics. Lancet. 1998;352(9143):1864
• Pohl F, Godfrey EL, Mudge E, Sheridan H. Fomitopsis betulina: a review. Molecules. 2019;24:2960

Phytochemistry and Pharmacology

• Zjawiony JK. Biologically active compounds from Aphyllophorales (polypore) fungi. J Nat Prod. 2004;67(2):300-310
• Schlegel B, et al. Piptamine, a new antibiotic produced by Piptoporus betulinus. J Antibiot. 2000;53(9):973-974
• Cyranka M, et al. Investigation of antiproliferative effect of extracts from Piptoporus betulinus. Pharmazie. 2011;66:468-472
• Piska K, et al. Edible mushroom Piptoporus betulinus as a source of biologically active compounds. Food Chem. 2019;285:141-149
• Grus T, et al. Anti-inflammatory lanostane triterpenoids from Fomitopsis betulina. Planta Med. 2019;85(18):1530
• Grienke U, et al. European medicinal polypores — a modern view on traditional uses. J Ethnopharmacol. 2014;154(3):564-583

Betulinic Acid

• Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci. 2008;9(6):1096-1107
• Yogeeswari P, Sriram D. Betulinic acid and its derivatives: a review on their biological properties. Curr Med Chem. 2005;12(6):657-666

Connections

• Oldest archaeological evidence of medicinal mushroom use (Otzi, ~3300 BC) — predates Dioscorides’ Agarikon description by ~3,400 years, giving birch polypore unique ethnomycological significance
• Compare with Agarikon: both are European polypore fungi in the Fomitopsidaceae with triterpenoid-driven pharmacology; agarikon has the longer written pharmacopoeial record, birch polypore has the older archaeological evidence
• Compare with Chaga: both grow on birch trees and share betulinic acid (from the birch substrate); chaga’s melanin/SOD antioxidant profile differs from birch polypore’s piptamine/polyporenic acid antimicrobial/anti-inflammatory profile
• Betulinic acid content connects to broader pharmaceutical interest in this compound for HIV and cancer — clinical translation potential exists via the pure compound even without whole-mushroom trials
• The adaptogenic category placement reflects the European general tonic tradition; less defined than the adaptogenic profiles of Reishi or Cordyceps but fills the otherwise sparse category
• Piptamine is unique among medicinal mushrooms as an antibiotic alkaloid, distinguishing birch polypore’s antimicrobial mechanism from the polysaccharide-driven immune activation of other species